Novo Nordisk and Eli Lilly and Co. LLY, manufacturers of diabetes drugs Ozempic and Mounjaro, are facing a lawsuit over claims of causing gastroparesis, CBS News reports.
The lawsuit, filed by personal injury law firm Morgan & Morgan, alleges a “failure to warn” about the potential side effect. The first case involves a 44-year-old Louisiana woman who has taken both drugs and experienced severe health issues, including multiple emergency room visits.
Attorney Paul Pennock stated that the firm is investigating 400 other inquiries from clients across 45 states. The drugs, known for aiding weight loss, are accused of causing gastroparesis, a condition that slows or stops the movement of food from the stomach to the small intestine.
“It is our opinion that these drugs are causing these problems. We think that the evidence is sufficient for us to be able to prove it or we would not have filed the case, and we intend to file many more in the coming days and weeks,” Pennock said.
Novo Nordisk acknowledged through a statement that gastrointestinal events are known side effects of the GLP-1 class, found in Ozempic. Eli Lilly stated that patient safety is their top priority.
Image by Natalia Varlei On Shutterstock
Read Next: Plastic Surgeon Hails ‘Miracle’ Weightloss Drug Ozempic, Says ‘They’re Better’ Than Botox
Engineered by Benzinga Neuro, Edited by Pooja Rajkumari
The GPT-4 Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
